d), predicts slow start in O1 (trading -0.54%) • Lundbeck: FDA panel backs claim of effectiveness for Brintellix in treating MDD (trading +10%) • Smith & Nephew H2 revs touch ahead, ebitda 3.5% ahead, guidance implies 3-4% d/g's (trading +0.09%) • Leonteq & DBS end pact on diverging interests on biz model & ex